Literature DB >> 8873291

Smoking and vulnerability for schizophrenia.

J de Leon1.   

Abstract

In several countries, the prevalence of smoking among schizophrenia patients is extraordinarily high (70% or greater). A State hospital survey demonstrated that after correcting for other factors, inpatients who have schizophrenia are more likely to be smokers than are persons in the normal population or even other chronic psychiatric inpatients. These findings suggest that neuroleptic treatment and the hospital environment cannot completely explain the high prevalence of smoking. The relationship between smoking and schizophrenia may be explained by a combination of three factors. One factor is the great difficulty for schizophrenia patients to quit smoking. Another is late onset: some schizophrenia patients start to smoke after the onset of psychosis. A third is increased early onset: schizophrenia patients may start daily smoking in greater numbers during adolescence (before the onset of their psychosis) than do persons in the normal U.S. population. Daily smoking is usually considered a sign of nicotine addiction and is used by epidemiological surveys to define the prevalence of smokers (most smokers smoke daily and very few smokers do not smoke every day). The increased early onset suggests that familial factors may increase the prevalence of smoking even among patients who have not yet shown psychotic symptoms. It is hypothesized that smoking among family members in families with genetic loading for schizophrenia may be a marker for those at risk of developing schizophrenia.

Entities:  

Mesh:

Year:  1996        PMID: 8873291     DOI: 10.1093/schbul/22.3.405

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  29 in total

1.  Illicit drug use in heavy smokers with and without schizophrenia.

Authors:  Kristen M Mackowick; Stephen J Heishman; Heidi J Wehring; Fang Liu; Robert P McMahon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-14       Impact factor: 4.939

2.  Is initiation of smoking associated with the prodromal phase of schizophrenia?

Authors:  Kaisa Riala; Helinä Hakko; Matti Isohanni; Anneli Pouta; Pirkko Räsänen
Journal:  J Psychiatry Neurosci       Date:  2005-01       Impact factor: 6.186

3.  Smoking cessation in patients with psychiatric disorders.

Authors:  Alan J Gelenberg; Jose de Leon; A Eden Evins; Joseph J Parks; Nancy A Rigotti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

Review 4.  Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia.

Authors:  John E Lisman; Joseph T Coyle; Robert W Green; Daniel C Javitt; Francine M Benes; Stephan Heckers; Anthony A Grace
Journal:  Trends Neurosci       Date:  2008-04-07       Impact factor: 13.837

Review 5.  Histone modifications, DNA methylation, and schizophrenia.

Authors:  David P Gavin; Rajiv P Sharma
Journal:  Neurosci Biobehav Rev       Date:  2009-10-30       Impact factor: 8.989

Review 6.  Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations.

Authors:  Douglas M Ziedonis; David Smelson; Richard N Rosenthal; Steven L Batki; Alan I Green; Renata J Henry; Ivan Montoya; Joseph Parks; Roger D Weiss
Journal:  J Psychiatr Pract       Date:  2005-09       Impact factor: 1.325

7.  Pharmacotherapy for smoking cessation in schizophrenia: a systematic review.

Authors:  Karolina Kozak; Tony P George
Journal:  Expert Opin Pharmacother       Date:  2020-02-03       Impact factor: 3.889

8.  Abnormal levels of vascular endothelial biomarkers in schizophrenia.

Authors:  Tanya T Nguyen; Sheena I Dev; Guanqing Chen; Sharon C Liou; Averria Sirkin Martin; Michael R Irwin; Judith E Carroll; Xin Tu; Dilip V Jeste; Lisa T Eyler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-09-23       Impact factor: 5.270

Review 9.  [Why do schizophrenic patients smoke?].

Authors:  K Cattapan-Ludewig; S Ludewig; E Jaquenoud Sirot; M Etzensberger; F Hasler
Journal:  Nervenarzt       Date:  2005-03       Impact factor: 1.214

10.  Chronic nicotine attenuates phencyclidine-induced impulsivity in a mouse serial reaction time task.

Authors:  Daniel Scott; Jane R Taylor
Journal:  Behav Brain Res       Date:  2013-11-14       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.